Clinical Trials of Novel Perspectives on Semaglutide with Injectable and Oral Formulations

• Bando, Hiroshi

抄録

Glucagon-Like Peptide 1 receptor agonists (GLP-1Ras) has been evaluated for its several positive effects in the treatment of type 2 diabetes mellitus (T2DM). Semaglutide has both of injectable and oral formulations, which is beneficial. Three clinical trials were conducted, which are Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN), Peptide Innovation for Early diabetes treatment (PIONEER) and Semaglutide Treatment Effect in People with Obesity (STEP). Among them, satisfactory clinical effects of reducing HbA1c and body weight have been observed. Oral semaglutide, Rybelsus has been effective oral hypoglycemic agent (OHA) and seems to be more prescribed widely.

収録刊行物

• SunText Review of Endocrine Care

  SunText Review of Endocrine Care 2 (1), 107-, 2022-01-31

  SunText Reviews

キーワード

• Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN)
• Peptide Innovation for Early Diabetes Treatment (PIONEER)
• Semaglutide Treatment Effect in People with Obesity (STEP)
• Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
• Rybelsus

詳細情報

• CRID: 1050572633033312768
• NII論文ID: 120007192117
• ISSN: 27715469
• Web Site: http://repo.lib.tokushima-u.ac.jp/116747
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles